First Seizure & Acute Symptomatic
First Seizure Evaluation & Acute Symptomatic Seizures
What You'll Learn
- First unprovoked seizure: recurrence risk is highest in the first 2 years, about 21–45% overall (AAN/AES 2015); risk is higher with prior brain insult, epileptiform EEG, significant imaging abnormality, or nocturnal seizure. Early treatment reduces early recurrence but does NOT alter long-term remission rates (FIRST & MESS trials).
- Treat after first seizure when recurrence risk ≥60% (AAN 2015 risk factors): epileptiform EEG, significant brain imaging abnormality, prior brain insult (stroke/trauma/infection), or nocturnal seizure
- Acute symptomatic seizures: occur within 7 days of structural insult or during active metabolic derangement; account for ~40% of all new-onset seizures; are NOT epilepsy
- Recurrence risk: acute symptomatic seizures carry 3–10× lower recurrence risk than a first unprovoked seizure
- Treatment priority: correct the underlying cause; long-term ASMs generally NOT indicated for isolated acute symptomatic seizures
- Key specifics: phenytoin is NOT effective for alcohol withdrawal seizures (use BZDs); eclampsia requires IV MgSO4, NOT standard ASMs; post-TBI 7-day prophylaxis does NOT prevent late epilepsy
HighYield Pearls
- ILAE 2014 epilepsy definition: ≥2 unprovoked seizures >24h apart OR 1 unprovoked + ≥60% 10-yr recurrence risk OR diagnosed epilepsy syndrome — one seizure CAN equal epilepsy
- AAN 2015 high-risk features that justify ASM after a first seizure: epileptiform EEG, structural MRI lesion, prior brain insult (stroke/TBI/infection), nocturnal seizure
- Early EEG matters: yield >50% if obtained within 24–48 h → order EEG early, not weeks later
- MRI > CT for first unprovoked seizure unless acute indication (trauma, focal deficit, anticoagulation)
- Acute symptomatic (provoked) seizures within 7 d of insult do NOT need chronic ASM — treat the cause; 3–10× lower recurrence than first unprovoked seizure
- Alcohol withdrawal seizures: 6–48 h after last drink → benzodiazepines, NOT phenytoin (phenytoin is ineffective here — classic board trap)
- Eclampsia: IV magnesium sulfate first-line, NOT lorazepam or phenytoin
- Severe TBI: 7-day levetiracetam prophylaxis (BTF) prevents EARLY post-traumatic seizures only — does NOT prevent late epilepsy
- Post-stroke seizures: EARLY (≤7 d) = acute symptomatic, no chronic ASM; LATE (>7 d) = high recurrence → treat as epilepsy
- Driving: counsel and document — typical US restriction is 3–12 months seizure-free; some states mandate physician reporting
🔍 Quick ReferenceClinical / workup · Acute symptomatic causes · Treatment decisions
Clinical / workup
- Witnessed GTC + tongue lateral bite + postictal confusion → true seizure (vs syncope = tip-of-tongue bite, rapid recovery)
- Todd’s paralysis (focal postictal weakness, resolves <24h) → focal-onset seizure, lateralizes to contralateral hemisphere
- EEG within 24–48 h of event → >50% yield for epileptiform discharges
- MRI lesion + epileptiform EEG after first seizure → ≥60% recurrence → meets ILAE epilepsy definition
- Pregnant + childbearing-age woman with new seizure → check βhCG before imaging/ASM choice
- Suspected CNS infection or SAH → LP after neuroimaging
- Seizure 6–48 h after last drink, often clustered, GTC → alcohol withdrawal seizure (BZD, not phenytoin)
- Postpartum/3rd-trimester HTN + proteinuria + seizure → eclampsia (IV MgSO4)
- HTN crisis / calcineurin inhibitor / chemo + seizure + parieto-occipital T2/FLAIR hyperintensity → PRES
- Na <125, hypoglycemia, hypoCa, hypoMg, uremia → metabolic acute symptomatic seizure (correct cause, no chronic ASM)
- Seizure ≤7 d after ischemic/hemorrhagic stroke → early post-stroke (acute symptomatic) — no chronic ASM
- Seizure >7 d after stroke or HSV encephalitis → late/unprovoked — high recurrence → treat as epilepsy
- Cocaine, amphetamines, bupropion, tramadol, MAOI, theophylline → drug-induced (proconvulsant) seizure
- Abrupt benzodiazepine or barbiturate cessation → withdrawal seizure
- First unprovoked seizure + normal EEG + normal MRI + no risk factors → defer ASM, counsel on recurrence
- First unprovoked seizure + any AAN high-risk feature → offer ASM (reduces 2-yr recurrence ~35%; does NOT change long-term remission)
- Severe TBI (GCS ≤8, contusion, depressed skull #) → 7-day levetiracetam prophylaxis (BTF)
- Acute symptomatic seizure from correctable metabolic cause → treat underlying derangement, NO chronic ASM
- Status epilepticus → see dedicated topic (benzodiazepine first, then 2nd-line ASM)
- All first-seizure patients → driving counseling + documentation (state-specific seizure-free interval)
Acute symptomatic / provoked causes
Treatment decisions / pearls
First Unprovoked Seizure
Recurrence Risk
- Overall: 21–45% at 2 years without treatment (AAN/AES 2015); risk is higher with prior brain insult, epileptiform EEG, significant imaging abnormality, or nocturnal seizure
- With epileptiform EEG: 60–70% at 2 years
- With remote structural lesion: 60–70% at 2 years
- Nocturnal seizure: higher than baseline
- Two or more risk factors: typically ≥60% → meets ILAE epilepsy definition
Key Evidence: FIRST & MESS Trials
- Immediate ASM treatment reduces recurrence by ~35% over 2 years
- Critical point: early treatment does NOT alter the long-term remission rate at 5 years
- Patients who defer treatment until a second seizure achieve the SAME long-term seizure freedom
When to Treat After First Seizure
Indications Favoring Treatment (recurrence risk ≥60%)
Per AAN 2015 practice guideline, the four canonical risk factors for seizure recurrence after a first unprovoked seizure are:
- Epileptiform EEG (interictal epileptiform discharges)
- Significant brain imaging abnormality
- Prior brain insult (stroke, trauma, infection)
- Nocturnal seizure
Additional considerations favoring treatment:
- Identification of an epilepsy syndrome (e.g., JME)
Indications Favoring Deferral
- Normal EEG, normal MRI, no risk factors
- Acute symptomatic seizure with correctable cause
- Patient preference after informed discussion
- Concerns about teratogenicity, cognitive side effects, or drug interactions
💎 Board Pearl
- AAN/AES guidelines: treatment decision after a first seizure should be individualized based on recurrence risk, patient preferences, and risk-benefit analysis
- A single unprovoked seizure + ≥60% recurrence risk = can diagnose epilepsy per ILAE 2014 definition (no need to wait for a second seizure)
Acute Symptomatic Seizures — Definition & Framework
ILAE Operational Definition
- Structural causes: seizure within 7 days of acute brain insult (stroke, TBI, CNS infection, neurosurgery)
- Metabolic/toxic causes: seizure during the active phase of the metabolic derangement
- CNS infections: seizure during active infection (may extend beyond 7 days)
- Account for ~40% of all new-onset seizures; incidence ~29–39 per 100,000/year
Why the Distinction Matters
- Acute symptomatic seizures are NOT epilepsy — even when recurrent
- 3–10× lower recurrence risk vs. first unprovoked seizure
- ~20% develop epilepsy within 10 years
- Mislabeling as epilepsy → unnecessary long-term ASMs, driving restrictions, psychosocial burden
Terminology Table
| Term | Definition | Clinical Significance |
|---|---|---|
| Acute symptomatic | Seizure within 7 days of acute insult or during active metabolic derangement | Provoked; NOT epilepsy; treat underlying cause |
| Unprovoked | No identifiable proximate cause or >7 days after brain insult | 2 unprovoked >24h apart = epilepsy; 1 + ≥60% recurrence = epilepsy |
| Early seizure | Seizure ≤7 days of TBI or stroke | Acute symptomatic; short-term treatment may be indicated |
| Late seizure | Seizure >7 days after TBI or stroke | Unprovoked; constitutes post-traumatic/post-stroke epilepsy |
| Remote symptomatic | Unprovoked seizure with prior brain insult >7 days earlier | Higher recurrence (~65%); generally warrants ASM |
Metabolic Thresholds for Acute Symptomatic Seizures
| Metabolic Cause | Seizure Threshold | Key Notes |
|---|---|---|
| Hypoglycemia | ≤36 mg/dL (2.0 mmol/L) | IV dextrose (D50W); seizures resolve with glucose correction |
| Hyperglycemia (nonketotic) | >450 mg/dL (25 mmol/L) with hyperosmolarity, nonketotic | Focal motor seizures/EPC characteristic; ASMs often ineffective until glucose corrected |
| Hyponatremia | ≤115 mEq/L (or rapid drop) | 3% hypertonic saline; avoid overcorrection (≤8 mEq/L/24h, or ≤10–12 in low-risk acute cases) to prevent osmotic demyelination |
| Hypocalcemia | ≤5.0 mg/dL (ionized <0.8 mmol/L) | IV calcium gluconate; correct concurrent hypomagnesemia |
| Hypomagnesemia | <0.8 mg/dL (0.3 mmol/L) | IV MgSO4; Mg2+ is endogenous NMDA blocker; must correct to enable Ca normalization |
| Uremia | Variable (BUN often ≥100) | Dialysis; avoid rapid urea clearance (dialysis disequilibrium); LEV preferred ASM |
| Hepatic encephalopathy | Variable | Lactulose, rifaximin; avoid valproate; often with asterixis |
💎 Board Pearl
- Nonketotic hyperglycemia + focal motor seizures/EPC = classic board association; ASMs often ineffective until glucose corrected
- Hypomagnesemia causes refractory hypocalcemia — always check and correct Mg first
Continue reading — sign in
The full note has more clinical pearls, tables, and board-focused tips. Free account, no fee.